340 related articles for article (PubMed ID: 31021028)
1. Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAF
Wang Z; Sun K; Jing C; Cao H; Ma R; Wu J
J Clin Lab Anal; 2019 Jul; 33(6):e22902. PubMed ID: 31021028
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Clinical Validity of Droplet Digital PCR to ARMS-PCR for BRAF V600E Mutation Detection in Thyroid Nodules.
Li X; Du H; Luo J; Ding W; Lai B; He J; Xu S; Zhang Y
J Clin Lab Anal; 2020 Nov; 34(11):e23458. PubMed ID: 32671901
[TBL] [Abstract][Full Text] [Related]
3. Detection of BRAF V600E mutation in fine-needle aspiration fluid of papillary thyroid carcinoma by droplet digital PCR.
Xu X; Ma X; Zhang X; Cao G; Tang Y; Deng X; Kang Z; Li M; Guan M
Clin Chim Acta; 2019 Apr; 491():91-96. PubMed ID: 30682328
[TBL] [Abstract][Full Text] [Related]
4. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
Chung KW; Yang SK; Lee GK; Kim EY; Kwon S; Lee SH; Park DJ; Lee HS; Cho BY; Lee ES; Kim SW
Clin Endocrinol (Oxf); 2006 Nov; 65(5):660-6. PubMed ID: 17054470
[TBL] [Abstract][Full Text] [Related]
5. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
[TBL] [Abstract][Full Text] [Related]
6. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
Lee ST; Kim SW; Ki CS; Jang JH; Shin JH; Oh YL; Kim JW; Chung JH
J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF
Kim JK; Seong CY; Bae IE; Yi JW; Yu HW; Kim SJ; Won JK; Chai YJ; Choi JY; Lee KE
Ann Surg Oncol; 2018 Jun; 25(6):1775-1781. PubMed ID: 29611028
[TBL] [Abstract][Full Text] [Related]
8. Detection of
Lu SY; Chen YC; Feng JL; Zhou QY; Chen J; Zhu CF; Guo MM; Zhang MM; Zhang QY; Lu M; Yang L; Wu J; Zhao SX; Song HD; Ye XP
Int J Endocrinol; 2022; 2022():6243696. PubMed ID: 35392249
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA Harboring the
Sato A; Tanabe M; Tsuboi Y; Niwa T; Shinozaki-Ushiku A; Seto Y; Murakami Y
Thyroid; 2021 Dec; 31(12):1822-1828. PubMed ID: 34541884
[No Abstract] [Full Text] [Related]
10. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies.
Zatelli MC; Trasforini G; Leoni S; Frigato G; Buratto M; Tagliati F; Rossi R; Cavazzini L; Roti E; degli Uberti EC
Eur J Endocrinol; 2009 Sep; 161(3):467-73. PubMed ID: 19574281
[TBL] [Abstract][Full Text] [Related]
11. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
Paek SH; Kim BS; Kang KH; Kim HS
World J Surg Oncol; 2017 Nov; 15(1):202. PubMed ID: 29132392
[TBL] [Abstract][Full Text] [Related]
12. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
13. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
[TBL] [Abstract][Full Text] [Related]
14. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z
Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846
[TBL] [Abstract][Full Text] [Related]
16. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
[TBL] [Abstract][Full Text] [Related]
17. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
18. [Expression of BRAF V600E mutation in different thyroid lesions].
Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
[TBL] [Abstract][Full Text] [Related]
19. Morphological features predictive for BRAF(V600E) mutation in papillary thyroid microcarcinomas.
Nechifor-Boilă AC; Szász EA; Descotes F; Berger N; Zahan AE; Loghin A; Ceteraş DM; Borda A
Rom J Morphol Embryol; 2018; 59(3):747-753. PubMed ID: 30534813
[TBL] [Abstract][Full Text] [Related]
20. DHPLC is a highly sensitive and rapid screening method to detect BRAF(V600E) mutation in papillary thyroid carcinoma.
Kim TE; Jung ES; Jung CK; Bae JS; Kim SN; Kim GS; Lee HN; Kang CS; Choi YJ
Exp Mol Pathol; 2013 Feb; 94(1):203-9. PubMed ID: 22691412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
